IN2015DN03733A - - Google Patents
Info
- Publication number
- IN2015DN03733A IN2015DN03733A IN3733DEN2015A IN2015DN03733A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A IN 3733DEN2015 A IN3733DEN2015 A IN 3733DEN2015A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A
- Authority
- IN
- India
- Prior art keywords
- scaffold
- ester
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725949P | 2012-11-13 | 2012-11-13 | |
| PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03733A true IN2015DN03733A (fi) | 2015-09-18 |
Family
ID=49725346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3733DEN2015 IN2015DN03733A (fi) | 2012-11-13 | 2013-11-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9765031B2 (fi) |
| EP (1) | EP2919779B1 (fi) |
| JP (1) | JP6272626B2 (fi) |
| CN (1) | CN104884057B (fi) |
| CA (1) | CA2889697C (fi) |
| IN (1) | IN2015DN03733A (fi) |
| WO (1) | WO2014078309A1 (fi) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| IN2015DN03733A (fi) * | 2012-11-13 | 2015-09-18 | Us Health | |
| US10329259B2 (en) | 2014-05-09 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| WO2016196646A1 (en) * | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
| EP3423448A1 (en) * | 2016-03-04 | 2019-01-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
| CN115335361A (zh) * | 2020-03-24 | 2022-11-11 | 因弗萨戈制药公司 | 无定形3,4-二苯基-4,5-二氢-1h-吡唑衍生物的固体分散物、包括它们的组合物及其作为大麻素cb1受体抑制剂的用途 |
| US20230159464A1 (en) * | 2020-04-07 | 2023-05-25 | Inversago Pharma Inc. | Process for producing 4,5-dihydro-1h-pyrazoles and intermediates |
| WO2023159317A1 (en) * | 2022-02-24 | 2023-08-31 | Inversago Pharma Inc. | Methods for treating subjects with abdominal obesity hypertriglyceridemia and/or impaired glucose |
| WO2023177568A1 (en) * | 2022-03-14 | 2023-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor modulating compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1236641A (en) | 1984-07-06 | 1988-05-10 | Motoaki Tanaka | Copolymer of lactic acid and glycolic acid and method for producing same |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| RU2245878C2 (ru) | 2000-03-23 | 2005-02-10 | Солвей Фармасьютикалс Б.В. | Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью |
| PT1373216E (pt) * | 2001-03-22 | 2005-05-31 | Solvay Pharm Bv | Derivados de 4,5-diidro-1h-pirazol que possuem actividade antagonista de cb1 |
| UA77441C2 (en) | 2001-09-21 | 2006-12-15 | 4,5-dihydro-1h-pyrazole derivatives as potent cb1 receptor antagonists, methods for their preparation (variants), intermediate, pharmaceutical composition and method for its preparation | |
| PL368441A1 (en) * | 2001-09-21 | 2005-03-21 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| KR20060131861A (ko) | 2004-01-30 | 2006-12-20 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 활성을 갖는 1,3,5-삼치환된4,5-디하이드로-1ｈ-피라졸 유도체 |
| EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
| EP2023920B1 (en) | 2006-05-05 | 2012-06-13 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| MX2010006109A (es) | 2007-12-10 | 2010-09-10 | 7Tm Pharma As | Moduladores de receptores de canabinoides. |
| US8288428B2 (en) | 2009-03-27 | 2012-10-16 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| WO2011044370A1 (en) | 2009-10-07 | 2011-04-14 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| AU2011329636B2 (en) | 2010-11-18 | 2016-05-19 | Jenrin Discovery | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| IN2015DN03733A (fi) * | 2012-11-13 | 2015-09-18 | Us Health | |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| US10329259B2 (en) | 2014-05-09 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| WO2016196646A1 (en) | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en active Application Filing
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
-
2017
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11485709B2 (en) | 2022-11-01 |
| US20230219896A1 (en) | 2023-07-13 |
| EP2919779A1 (en) | 2015-09-23 |
| WO2014078309A1 (en) | 2014-05-22 |
| CN104884057A (zh) | 2015-09-02 |
| CN104884057B (zh) | 2019-08-20 |
| CA2889697A1 (en) | 2014-05-22 |
| US20230202983A1 (en) | 2023-06-29 |
| US9765031B2 (en) | 2017-09-19 |
| US11939297B2 (en) | 2024-03-26 |
| JP2015536997A (ja) | 2015-12-24 |
| US20160039766A1 (en) | 2016-02-11 |
| US20200331861A1 (en) | 2020-10-22 |
| US10683270B2 (en) | 2020-06-16 |
| JP6272626B2 (ja) | 2018-01-31 |
| WO2014078309A8 (en) | 2015-05-21 |
| US20180022705A1 (en) | 2018-01-25 |
| EP2919779B1 (en) | 2021-01-06 |
| CA2889697C (en) | 2023-03-14 |
| US20180022706A1 (en) | 2018-01-25 |
| US10787419B2 (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03733A (fi) | ||
| NO2021034I1 (no) | pemigatinib or a pharmaceutically acceptable salt thereof | |
| NO2022043I1 (en) | Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride | |
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| HK1208801A1 (en) | Orally administered medical composition | |
| HUE051459T2 (hu) | Excípiensek nikotin-tartalmú gyógyászati készítményekhez | |
| EP2931730A4 (en) | 4-PYRIDINONETRIAZINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
| DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
| EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
| EP2560624A4 (en) | THERAPEUTIC FORMULATION TO REDUCE THE SIDE EFFECTS OF MEDICATION | |
| EP3082817A4 (en) | Compositions for drug administration | |
| IL231485A0 (en) | Medicinal compounds are immune to interference | |
| GB201216018D0 (en) | Pharmacologically active compounds | |
| MY187718A (en) | Pharmaceutical formulations | |
| HK1205462A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| HRP20190050T1 (hr) | Farmaceutski pripravci za kombinacijsku terapiju | |
| EP2731605A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | |
| EP2877469A4 (en) | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
| HK1206292A1 (en) | Medicament administration | |
| HUP1100641A2 (en) | A new diaza-benzofluoranthene derivate as drug | |
| DK2420219T3 (da) | Indgivelsesport | |
| EP2864328B8 (en) | Pharmaceutically active compounds | |
| EP2842554A4 (en) | BRONCHOLYTIC PRODUCT BASED ON PROSTAGLANDINE | |
| EP2688566A4 (en) | ANTICANCER THERAPEUTIC AGENTS | |
| EP3069311A4 (en) | Delivering a publication to a subscriber |